---
input_text: 'WTX101 - an investigational drug for the treatment of Wilson disease.INTRODUCTION:
  Wilson disease (WD) is a genetic disorder in which excess toxic copper accumulates
  in the liver, brain, and other tissues leading to severe and life-threatening symptoms.
  Copper overload can be assessed as non-ceruloplasmin-bound copper non-ceruloplasmin-bound
  copper (NCC) in blood. Current therapies are limited by efficacy, safety concerns,
  and multiple-daily dosing. Areas covered: This article reviews the literature on
  WTX101 (bis-choline tetrathiomolybdate), an oral first-in-class copper-protein-binding
  agent in development for the treatment of WD. Expert opinion: In a proof-of-concept
  phase II trial, once-daily WTX101 over 24 weeks rapidly lowered NCC levels and this
  was accompanied by improved neurological status without apparent initial drug-induced
  paradoxical worsening, reduced disability, stable liver function, with a favorable
  safety profile. WTX101 directly removes excess copper from intracellular hepatic
  copper stores and also forms an inert tripartite complex with copper and albumin
  in the circulation and promotes biliary copper excretion. These mechanisms may explain
  the rapid biochemical and clinical improvements observed. A phase III trial of WTX101
  is ongoing and results are eagerly awaited to confirm if WTX101 can improve the
  treatment of this devastating disease.'
raw_completion_output: |-
  primary_disease: Wilson disease

  medical_actions: Assessment of non-ceruloplasmin-bound copper (NCC) levels in blood; Oral administration of WTX101; Lowering NCC levels; Improved neurological status; Reduced disability; Stable liver function; Biliary copper excretion

  symptoms: Excess toxic copper accumulation in the liver, brain, and other tissues; Severe and life-threatening symptoms

  chemicals: WTX101 (bis-choline tetrathiomolybdate); Copper

  action_annotation_relationships: Assessment of non-ceruloplasmin-bound copper (NCC) levels in blood TREATS Excess toxic copper accumulation IN Wilson disease; Oral administration of WTX101 (with WTX101) TREATS Excess toxic copper accumulation IN Wilson disease; Lowering NCC levels (with WTX101) TREATS Excess toxic copper accumulation IN Wilson disease; Improved neurological status (with WTX101) TREATS Severe and life-threatening symptoms IN Wilson disease; Reduced disability (with WTX101) TREATS Severe and life-threatening symptoms IN Wilson disease; Stable liver function (with WTX101) PREVENTS Severe and life-threatening symptoms IN Wilson disease; Biliary copper excretion (with WTX101) TREATS Excess toxic copper accumulation IN Wilson disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Biliary copper excretion (with WTX101) TREATS Excess toxic copper accumulation IN Wilson disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - Assessment of non-ceruloplasmin-bound copper (NCC) levels in blood
    - Oral administration of WTX101
    - Lowering NCC levels
    - Improved neurological status
    - Reduced disability
    - Stable liver function
    - Biliary copper excretion
  symptoms:
    - Excess toxic copper accumulation in the liver, brain, and other tissues
    - Severe and life-threatening symptoms
  chemicals:
    - WTX101 (bis-choline tetrathiomolybdate)
    - CHEBI:28694
  action_annotation_relationships:
    - subject: Assessment of non-ceruloplasmin-bound copper (NCC) levels in blood
      predicate: TREATS
      object: Excess toxic copper accumulation
      qualifier: MONDO:0010200
      subject_extension: non-ceruloplasmin-bound copper (NCC)
    - subject: Oral administration
      predicate: TREATS
      object: Excess toxic copper accumulation
      qualifier: MONDO:0010200
      subject_qualifier: with WTX101
      subject_extension: WTX101
    - subject: Lowering NCC levels
      predicate: TREATS
      object: Excess toxic copper accumulation
      qualifier: MONDO:0010200
      subject_extension: WTX101
    - subject: Improved neurological status
      predicate: TREATS
      object: Severe and life-threatening symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with WTX101
      object_qualifier: Severe and life-threatening
      subject_extension: WTX101
    - subject: Reduced disability
      predicate: TREATS
      object: symptoms
      qualifier: MONDO:0010200
      subject_extension: WTX101
      object_extension: Severe and life-threatening
    - subject: Stable liver function
      predicate: PREVENTS
      object: Severe and life-threatening symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with WTX101
      subject_extension: WTX101
    - subject: Biliary copper excretion
      predicate: TREATS
      object: Excess toxic copper accumulation
      qualifier: MONDO:0010200
      subject_qualifier: with WTX101
      subject_extension: WTX101
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: HP:0001695
    label: cardiac arrest
  - id: HP:0001685
    label: myocardial fibrosis
  - id: HP:0001663
    label: ventricular fibrillation
  - id: CHEBI:38161
    label: Chelating agents
  - id: MAXO:0000016
    label: Cell therapy
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0001392
    label: Hepatic disease
  - id: CHEBI:30703
    label: Tetrathiomolybdate (TTM)
  - id: CHEBI:28694
    label: Copper (Cu)
  - id: CHEBI:18248
    label: Iron (Fe)
  - id: CHEBI:27363
    label: Zinc (Zn)
  - id: CHEBI:82594
    label: Ferritin (SFr)
  - id: HP:0001744
    label: Splenomegaly
  - id: HP:0001541
    label: Ascites
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:46195
    label: Paracetamol
  - id: HP:0006554
    label: Acute Liver Failure
  - id: CHEBI:21547
    label: N-acetyl aspartate (NAA)
  - id: CHEBI:15354
    label: Choline (Cho)
  - id: CHEBI:157802
    label: Creatine (Cr)
  - id: MAXO:0009095
    label: Treatment with zinc
  - id: HP:0001399
    label: Liver failure
  - id: CHEBI:7959
    label: d-penicillamine
  - id: CHEBI:39501
    label: Trientine
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0000376
    label: liver biopsy
  - id: HP:0033771
    label: pleuritic chest pain
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: MAXO:0035080
    label: apoptosis assays
  - id: CHEBI:33709
    label: amino acids
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: HP:0001342
    label: Intracerebral hemorrhage
  - id: MONDO:0014789
    label: CCDC115-CDG
  - id: HP:0003124
    label: hypercholesterolemia
  - id: HP:0003155
    label: elevated alkaline phosphatases
  - id: MAXO:0000533
    label: Molecular genetic testing
  - id: MAXO:0001181
    label: Serum alkaline phosphatase measurement
  - id: HP:0032199
    label: Abnormal prothrombin time
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: CHEBI:50868
    label: Penicillamine
  - id: HP:0001878
    label: hemolytic anemia
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0005135
    label: T wave abnormality
  - id: HP:0011703
    label: sinus tachycardia
  - id: HP:0001688
    label: sinus bradycardia
  - id: HP:0006682
    label: premature ventricular contraction
  - id: CHEBI:35623
    label: antiepileptics
  - id: HP:0001410
    label: Hepatic dysfunction
  - id: CHEBI:62984
    label: Zinc acetate
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (AML)
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0004808
    label: Acute Myeloid Leukemia
  - id: HP:0001336
    label: Myoclonus
  - id: HP:0001250
    label: Epileptic seizures
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0001337
    label: Tremor
  - id: HP:0002315
    label: Headache
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: HP:0001882
    label: leukopenia
  - id: MONDO:0007329
    label: Indian childhood cirrhosis
  - id: HP:0001945
    label: fever
  - id: HP:0002908
    label: direct hyperbilirubinemia
  - id: HP:0002910
    label: elevated transaminases
  - id: HP:0001903
    label: anemia
  - id: HP:0001409
    label: portal hypertension
  - id: MONDO:0004789
    label: Cholangitis
  - id: MAXO:0000127
    label: Genetic analysis
  - id: MONDO:0007256
    label: Hepatocellular carcinoma (HCC)
  - id: CHEBI:26708
    label: NA
  - id: HP:0001402
    label: Hepatocellular carcinoma (HCC)
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0019542
    label: Acute Liver Failure
  - id: HP:0002359
    label: Frequent Falls
  - id: MONDO:0015143
    label: Rare movement disorders
  - id: HP:0100022
    label: Movement disorders
  - id: HP:0033329
    label: Abnormal postural reflex
  - id: MONDO:0002492
    label: acute kidney injury
  - id: MAXO:0000973
    label: slit-lamp examination
  - id: HP:0033429
    label: Neuroinflammation
  - id: CHEBI:18291
    label: manganese
  - id: CHEBI:28938
    label: ammonia
  - id: HP:0001433
    label: hepatosplenomegaly
  - id: HP:0002904
    label: hyperbilirubinemia
  - id: HP:0003256
    label: coagulopathy
  - id: MONDO:0012105
    label: ANCA-associated Vasculitis
  - id: HP:0002105
    label: Hemoptysis
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0002907
    label: Microscopic hematuria
  - id: HP:0000093
    label: Proteinuria
  - id: CHEBI:24261
    label: Glucocorticoid
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:8764
    label: Mycophenolate mofetil
  - id: HP:0040223
    label: pulmonary hemorrhage
  - id: HP:0000790
    label: hematuria
  - id: MONDO:0100193
    label: End-stage liver diseases
  - id: HP:0002040
    label: Esophageal varices
  - id: HP:0100626
    label: End-stage liver diseases
  - id: MONDO:0017014
    label: children
  - id: HP:0200123
    label: chronic hepatitis
  - id: HP:0001397
    label: steatosis
  - id: CHEBI:28787
    label: targeted next-generation sequencing (NGS)
  - id: MAXO:0000527
    label: Physical examination
  - id: MAXO:0010200
    label: Abdominal ultrasonography (Abdl Ur)
  - id: HP:0010837
    label: Decreased serum ceruloplasmin
  - id: CHEBI:37708
    label: Alanine transaminase (ALT)
  - id: CHEBI:76649
    label: Aspartate transaminase (AST)
  - id: HP:0200120
    label: chronic active hepatitis
  - id: HP:0002896
    label: liver cancer
  - id: HP:0002354
    label: memory dysfunction
  - id: HP:0100543
    label: cognitive impairment
  - id: CHEBI:23414
    label: CuSO4
  - id: CHEBI:16856
    label: glutathione (GSH)
  - id: CHEBI:566274
    label: malondialdehyde (MDA)
  - id: CHEBI:31882
    label: N-methyl-D-aspartate
  - id: HP:0002885
    label: Mallory-Denk body (MDB) formation
  - id: CHEBI:16990
    label: Bilirubin
  - id: HP:0001266
    label: choreoathetosis
  - id: MAXO:0009101
    label: early intervention
  - id: HP:0012594
    label: microalbuminuria
  - id: HP:0002150
    label: hypercalciuria
  - id: CHEBI:888
    label: Sodium dimercaptopropanesulfonate (DMPS)
  - id: CHEBI:35176
    label: zinc sulfate
  - id: MAXO:0000137
    label: PET scans
  - id: CHEBI:17234
    label: Glucose
  - id: MONDO:0005556
    label: Lupus Nephritis
  - id: MAXO:0000165
    label: Treatment with diuretics
  - id: CHEBI:35498
    label: Diuretics
  - id: CHEBI:33281
    label: Antibiotics
  - id: CHEBI:50503
    label: Laxatives
  - id: CHEBI:74067
    label: Copper(II)
  - id: CHEBI:6801
    label: 2-N, N-dimethylcarbamimidoyl (metformin)
  - id: HP:0004787
    label: Fulminant hepatitis
  - id: MAXO:0010026
    label: Zinc supplementation
  - id: HP:0011967
    label: Copper deficiency
  - id: CHEBI:38127
    label: Thiocarbamate
  - id: CHEBI:25548
    label: Nitrilotriacetate
  - id: CHEBI:16494
    label: Lipoic acid
  - id: CHEBI:30313
    label: Lipoate
  - id: MONDO:0010651
    label: Menkes disease
  - id: MAXO:0000647
    label: chemotherapy (with epirubicin, cyclophosphamide, docetaxel, paclitaxel)
  - id: HP:0032408
    label: lump in breast
  - id: CHEBI:47898
    label: epirubicin
  - id: CHEBI:4672
    label: docetaxel
  - id: CHEBI:45863
    label: paclitaxel
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:18132
    label: CHOP
  - id: HP:0002665
    label: Lymphoma
  - id: HP:0001947
    label: renal tubular acidosis
  - id: HP:0003355
    label: aminoaciduria
  - id: HP:0000787
    label: nephrolithiasis
  - id: HP:0011675
    label: arrhythmia
  - id: HP:0001638
    label: cardiomyopathy
  - id: HP:0012332
    label: autonomic dysfunction
  - id: HP:0000789
    label: infertility
  - id: HP:0000829
    label: hypoparathyroidism
